Metraipolis › archive › dc_1669a9d41337
Immunobridging Analysis of Pemivibart for the Treatment of COVID-19: A Therapeutic Gap for the Immune-Compromised Population Remains — Europe PMC PMID:42639460
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42639460
- DOI
- 10.1093/ofid/ofag168
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-03T12:25:23.371Z
- SHA-256 of the archived text
c5b6920b1607db8ecd412822da2821756210492b903eabb29bf21afb61d7eafd- Stable URL of this page
https://metraipolis.com/documento/dc_1669a9d41337
How to cite
Immunobridging Analysis of Pemivibart for the Treatment of COVID-19: A Therapeutic Gap for the Immune-Compromised Population Remains — Europe PMC PMID:42639460 — Europe PMC (en), https://europepmc.org/article/MED/42639460 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_1669a9d41337 (Metraipolis archive dc_1669a9d41337, sha256 c5b6920b1607db8ecd412822da2821756210492b903eabb29bf21afb61d7eafd)
BibTeX
@misc{dc1669a9d41337,
title = {Immunobridging Analysis of Pemivibart for the Treatment of COVID-19: A Therapeutic Gap for the Immune-Compromised Population Remains — Europe PMC PMID:42639460},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42639460},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_1669a9d41337; sha256 c5b6920b1607db8ecd412822da2821756210492b903eabb29bf21afb61d7eafd},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42639460. Agents can read the archived copy with the MCP tool read_document.